Refractory Chronic Lymphocytic Leukemia (CLL) (DBCOND0146058)

Identifiers

Synonyms

Chronic Lymphocytic Leukemia (CLL) - Refractory / CLL, Refractory / Chronic, refractory Lymphocytic leukaemia / Refractory CLL / Refractory Chronic Lymphocytic Leukemia / Chronic lymphocytic leukemia refractory / Chronic Lymphocytic Leukaemia Refractory / Chronic, refractory Lymphocytic Leukemia

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Duvelisib	An inhibitor of phosphatidylinositol 3-kinase delta and gamma used to treat relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.	Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoformtarget Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoformtarget
Lenalidomide	A thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome.	Prostaglandin G/H synthase 2target Tumor necrosis factor ligand superfamily member 11target Cadherin-5target Protein cereblontarget ATP-dependent translocase ABCB1transporter Tumor necrosis factortarget
Lisocabtagene maraleucel	A CAR T-cell therapy for treatment resistant or more severe B-cell lymphomas.	B-lymphocyte antigen CD19target
Ofatumumab	An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications.	B-lymphocyte antigen CD20target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT00185679	Haploid Allogeneic Transplant Using the CliniMACS System	No drug interventions	treatment	2	terminated
NCT05621148	REfractorinesS to Ibrutinib BTKi and Systemic Targeted Therapy	No drug interventions	Not Available	Not Available	completed
NCT04512105	Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia	Pitavastatin Venetoclax	treatment	1	active_not_recruiting
NCT03884829	A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS	No drug interventions	treatment	1	unknown_status
NCT05828589	A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies	No drug interventions	treatment	1	recruiting
NCT06343376	Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT04578600	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Azacitidine Lenalidomide Obinutuzumab	treatment	1	active_not_recruiting
NCT04892277	CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT01126502	Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Alvespimycin	treatment	1	terminated
NCT04195633	Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies	Cyclophosphamide Cyclosporine Filgrastim Fludarabine Mycophenolate mofetil Mycophenolic acid Treosulfan	treatment	2	recruiting
NCT01638533	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction	Romidepsin	treatment	1	active_not_recruiting
NCT04624633	Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL	Acalabrutinib Ublituximab Umbralisib	treatment	2	active_not_recruiting
NCT00089154	Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Apolizumab	treatment	2	completed
NCT00006251	Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT02427451	Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia	Ibrutinib Obinutuzumab Venetoclax	treatment	1 / 2	active_not_recruiting
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT05246345	Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia	No drug interventions	Not Available	Not Available	recruiting
NCT00101205	Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma	Etoposide Oxaliplatin	treatment	1	terminated
NCT00095797	XK469R in Treating Patients With Refractory Hematologic Cancer	No drug interventions	treatment	1	completed
NCT00303797	Sorafenib and Bortezomib in Treating Patients With Advanced Cancer	Bortezomib Sorafenib	treatment	1	completed
NCT02948283	Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia	Metformin Ritonavir	treatment	1	completed
NCT00608361	Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Dasatinib	treatment	1	completed
NCT01619761	NK Cells in Cord Blood Transplantation	Cyclophosphamide Fludarabine Lenalidomide Mechlorethamine Mycophenolate mofetil Natural Killer Cell Rituximab Tacrolimus	treatment	1	unknown_status
NCT01129193	AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma	AR-42	treatment	1	completed
NCT02181478	Intra-Osseous Co-Transplant of UCB and hMSC	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	0	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT01254578	Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers	Lenalidomide	treatment	1	completed
NCT03579888	CD19-Specific T Cells Post AlloSCT	Cyclophosphamide Fludarabine	treatment	1	terminated
NCT04205409	Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies	Nivolumab	treatment	2	active_not_recruiting
NCT01567709	Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma	Alisertib Vorinostat	treatment	1	completed
NCT01076556	Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Alvocidib Cyclophosphamide Rituximab	treatment	1	terminated
NCT00933985	Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia	Dexrazoxane Doxorubicin Obatoclax Vincristine	treatment	1	terminated
NCT00068315	Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Bortezomib Bortezomib D-mannitol Fludarabine Rituximab	treatment	1	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT02160015	Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery	Ibrutinib Lenalidomide Rituximab	treatment	1	active_not_recruiting
NCT04169737	Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Acalabrutinib Obinutuzumab Tyrosine Venetoclax	treatment	2	recruiting
NCT00118352	Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01886859	Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Ibrutinib Lenalidomide	treatment	1	completed
NCT02225275	Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Lenalidomide Obinutuzumab	treatment	2	terminated
NCT02685670	Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphoma	Cyclophosphamide Fludarabine	treatment	1 / 2	unknown_status
NCT00723099	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00005799	Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT01369849	Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Bendamustine Rituximab	treatment	1 / 2	completed
NCT00366418	Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia	Rituximab	treatment	1	completed
NCT02240719	Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bendamustine Everolimus	treatment	1	completed
NCT00060424	Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT03639324	Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL	No drug interventions	treatment	1	withdrawn
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT04941716	Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Acalabrutinib Tyrosine Venetoclax	treatment	2	recruiting
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT00104858	Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	completed
NCT01475058	CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant	Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes	treatment	1 / 2	completed
NCT00014235	Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT01093586	Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Cyclosporine Methylprednisolone Methylprednisolone hemisuccinate Mycophenolate mofetil	treatment	2	completed
NCT00735930	Lenalidomide and Alvocidib in Treating Patients With Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Alvocidib Lenalidomide	treatment	1	completed
NCT00006226	Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	Thalidomide	treatment	2	completed
NCT00303966	Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia	Sorafenib	treatment	2	terminated
NCT00003166	Bryostatin and Vincristine in B-Cell Malignancies	Bryostatin 1 Sulfate ion Vincristine	treatment	1	completed
NCT00003620	Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia	Alvocidib	treatment	2	completed
NCT00027820	Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00058227	Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma	Alvocidib Fludarabine Rituximab	treatment	1	completed
NCT00789776	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Natural Killer Cell Tacrolimus	treatment	1 / 2	completed
NCT03185494	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22	No drug interventions	treatment	1 / 2	unknown_status
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01212380	Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)	Carfilzomib	treatment	1	completed
NCT04007029	Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia	Cyclophosphamide Fludarabine Tocilizumab	treatment	1	recruiting
NCT01864889	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19	No drug interventions	treatment	Not Available	unknown_status
NCT04305444	Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas	Everolimus Pomalidomide	treatment	2	active_not_recruiting
NCT02285244	Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation	Sotrastaurin	treatment	2	withdrawn
NCT00058240	Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma	Alvocidib	treatment	1 / 2	completed
NCT03110640	Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma	Cyclophosphamide Fludarabine	treatment	1	unknown_status
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT01735604	Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy	No drug interventions	treatment	1 / 2	unknown_status
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00060372	Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer	Ipilimumab Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT00040846	Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies	Alemtuzumab Cyclosporine Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT00398112	Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Sunitinib	treatment	2	completed
NCT01231412	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil Sirolimus	treatment	3	completed
NCT00290810	Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Bevacizumab	treatment	2	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT04781855	Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation	Ibrutinib Ipilimumab Nivolumab	treatment	1	active_not_recruiting
NCT01523223	Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies	Therapeutic allogeneic lymphocytes	treatment	1	completed
NCT04029038	Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma	Cyclophosphamide Fludarabine	treatment	1 / 2	withdrawn
NCT01408043	Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma	Etoposide Filgrastim Plerixafor	treatment	Not Available	terminated
NCT00005803	Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma	Beta-D-Glucose Carmustine Cyclophosphamide Cyclosporine Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01326702	Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors	Bendamustine Rituximab Veliparib	treatment	1 / 2	completed
NCT00009984	Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer	Fludarabine Thalidomide	treatment	2	terminated
NCT04978779	A Study to Evaluate VIP152 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome	Enitociclib	treatment	1	terminated
NCT06191887	B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT02869633	Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant	Ibrutinib	treatment	2	completed
NCT00918333	Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma	Everolimus Panobinostat	treatment	1 / 2	completed
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT02756897	Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia	Ibrutinib Venetoclax	treatment	2	active_not_recruiting
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT03045328	Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL	Ibrutinib Venetoclax	treatment	2	completed
NCT00711828	Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma	Bortezomib Cyclophosphamide Dexamethasone Rituximab	treatment	2	completed
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00098371	Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	Alvocidib	treatment	2	terminated
NCT00075478	Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	3	completed
NCT00079378	Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	2'-Deoxycytidine Decitabine Valproic acid	treatment	1	completed
NCT00947388	Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL)	Alemtuzumab Bendamustine	treatment	1	terminated
NCT00098488	17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	Rituximab Tanespimycin	treatment	1	terminated
NCT05418088	Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies	Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT02168907	CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma	Bendamustine Devimistat Lipoic acid Rituximab	treatment	1	terminated
NCT01269385	Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia	Alemtuzumab Odetiglucan Rituximab	treatment	1 / 2	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT00621452	Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma	Aldesleukin Cyclophosphamide	treatment	1	completed
NCT01251575	Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil Sirolimus	treatment	2	completed
NCT03097770	Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20	No drug interventions	treatment	1 / 2	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT01658319	Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies	Fludarabine Methoxyamine	treatment	1	completed
NCT01865617	Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia	No drug interventions	treatment	1 / 2	completed
NCT02109224	Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	Ibrutinib	treatment	1	terminated
NCT03878524	Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial	Abemaciclib Abiraterone Afatinib Albumin human Avobenzone Bevacizumab Bicalutamide Bortezomib Bortezomib D-mannitol Cabazitaxel Cabozantinib Capecitabine Carboplatin Celecoxib Cobimetinib Copanlisib Dabrafenib Dacomitinib Darolutamide Dasatinib Daunorubicin Doxorubicin Durvalumab Enasidenib Entrectinib Enzalutamide Erlotinib Everolimus Fluorouracil Idelalisib Imatinib Ipilimumab Lenvatinib Leucovorin Lorlatinib Losartan Neratinib Nivolumab Octinoxate Olaparib Oxaliplatin Paclitaxel Palbociclib Panobinostat Pembrolizumab Pertuzumab Ponatinib Regorafenib Ruxolitinib Sirolimus Sorafenib Sunitinib Trametinib Trastuzumab emtansine Tretinoin Vemurafenib Venetoclax Vismodegib Vorinostat	treatment	1	terminated
NCT00321724	AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia	Cediranib	treatment	2	completed
NCT00003196	Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma	Cyclosporine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT03010358	Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma	Entospletinib Obinutuzumab	treatment	1 / 2	completed
NCT00053963	FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia	Romidepsin	treatment	1	completed
NCT00005786	Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia	Arsenic trioxide Arsenous acid	treatment	Not Available	terminated
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Sunitinib	treatment	2	terminated
NCT01029366	CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy	Tisagenlecleucel	treatment	1	completed
NCT01441882	Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia	Dasatinib	treatment	2	completed
NCT01515176	Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia	Dinaciclib Ofatumumab	treatment	1 / 2	completed
NCT01053494	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	No drug interventions	supportive_care	Not Available	completed
NCT01008462	Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	Beta-D-Glucose Carmustine Cyclophosphamide Cytarabine Etoposide Fludarabine Mechlorethamine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT02332980	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	Ibrutinib Idelalisib Pembrolizumab	treatment	2	completed
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT00867529	Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma	Rituximab	treatment	2	completed
NCT02005289	Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL	Lenalidomide Tafasitamab	treatment	2	active_not_recruiting
NCT02303392	Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma	Escitalopram Ibrutinib Selinexor	treatment	1	unknown_status
NCT02706392	Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies	No drug interventions	treatment	1	terminated
NCT00086840	CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Menthol Temsirolimus	treatment	2	terminated
NCT00288067	Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma	Fenretinide Rituximab	treatment	1 / 2	terminated
NCT00536601	High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors	Busulfan Carboplatin Carmustine Cyclophosphamide Etoposide Melphalan Thiotepa	treatment	Not Available	completed
NCT00105001	Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Sirolimus Tacrolimus	treatment	2	completed
NCT04230304	Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study	Daratumumab Ibrutinib	treatment	2	active_not_recruiting
NCT00845104	Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatment	Bevacizumab Fludarabine Rituximab	treatment	2	withdrawn
NCT00290472	CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia	Menthol Temsirolimus	treatment	2	completed
NCT03961672	Intermittent Duvelisib Dosing in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Duvelisib	treatment	2	active_not_recruiting
NCT03884972	Trabectedin and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Resistant or Intolerant to a BTK Inhibitor	Trabectedin Venetoclax	treatment	1	withdrawn
NCT00103272	17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer	Bortezomib Bortezomib D-mannitol Tanespimycin	treatment	1	terminated
NCT00017472	Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia	Apolizumab	treatment	1	completed
NCT03479268	Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma	Ibrutinib Pevonedistat	treatment	1	active_not_recruiting
NCT00301769	SJG-136 in Treating Patients With Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndromes, Blastic Phase Chronic Myelogenous Leukemia, or Chronic Lymphocytic Leukemia	SJG-136	treatment	1	terminated
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT00612612	Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia	Fludarabine Obatoclax Rituximab	treatment	1	terminated
NCT02420912	Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation	Ibrutinib Nivolumab	treatment	2	completed
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Lenalidomide Rituximab	treatment	2	terminated
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT01251250	Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia	No drug interventions	treatment	1	withdrawn
NCT02614508	Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia	Buparlisib Ibrutinib Ofatumumab	treatment	1	terminated
NCT03853616	MB-CART19.1 R/r CD19+ B-cell Malignancies (BCM)	Tisagenlecleucel	treatment	1 / 2	recruiting
NCT05705570	A Phase I Clinical Trial Using Genetically Engineered Autologous T Cells to Express Chimeric Antigen Receptor (CAR) for Treatment of Patients With Refractory or Relapsed CD19-positive B Lymphoid Malignancies	Cyclophosphamide Fludarabine	treatment	1	not_yet_recruiting